DK3834823T3 - Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog - Google Patents

Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog Download PDF

Info

Publication number: DK3834823T3
Authority: DK; Denmark
Prior art keywords: rapalog; preparation; methods; synthetic nanocarriers; low hlb
Prior art date: 2014-11-05

Application number

DK20204014.3T

Other languages

English (en)

Inventor

Conlin O'neil

Aaron P Griset

David H Altreuter

Original Assignee

Cartesian Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-05

Filing date

2015-11-05

Publication date

2024-04-08

2015-11-05 Application filed by Cartesian Therapeutics Inc filed Critical Cartesian Therapeutics Inc

2024-04-08 Application granted granted Critical

2024-04-08 Publication of DK3834823T3 publication Critical patent/DK3834823T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Nanotechnology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Dispersion Chemistry (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Cosmetics (AREA)
Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Compositions Of Macromolecular Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Investigating Or Analysing Biological Materials (AREA)
Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

DK20204014.3T 2014-11-05 2015-11-05 Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog DK3834823T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462075864P	2014-11-05	2014-11-05
US201462075866P	2014-11-05	2014-11-05
EP15798601.9A EP3215133B1 (en)	2014-11-05	2015-11-05	Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog

Publications (1)

Publication Number	Publication Date
DK3834823T3 true DK3834823T3 (da)	2024-04-08

Family

ID=54697646

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK21156943.9T DK3906918T3 (da)	2014-11-05	2015-11-05	Fremgangsmåder og sammensætninger i forbindelse med syntetiske nanobærere med rapamycin i en stabil, supermættet tilstand
DK15857076.2T DK3215192T3 (da)	2014-11-05	2015-11-05	Fremgangsmåder og sammensætninger i forbindelse med syntetiske nanobærere med rapamycin i en stabil, supermættet tilstand
DK15798601.9T DK3215133T3 (da)	2014-11-05	2015-11-05	Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog
DK20204014.3T DK3834823T3 (da)	2014-11-05	2015-11-05	Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
DK21156943.9T DK3906918T3 (da)	2014-11-05	2015-11-05	Fremgangsmåder og sammensætninger i forbindelse med syntetiske nanobærere med rapamycin i en stabil, supermættet tilstand
DK15857076.2T DK3215192T3 (da)	2014-11-05	2015-11-05	Fremgangsmåder og sammensætninger i forbindelse med syntetiske nanobærere med rapamycin i en stabil, supermættet tilstand
DK15798601.9T DK3215133T3 (da)	2014-11-05	2015-11-05	Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog

Country Status (23)

Country	Link
US (3)	US20160128986A1 (da)
EP (6)	EP3906918B1 (da)
JP (5)	JP7218089B2 (da)
KR (2)	KR102601922B1 (da)
CN (5)	CN113244191A (da)
AU (4)	AU2015342968B2 (da)
BR (3)	BR122021025344B1 (da)
CA (2)	CA2966850C (da)
CY (1)	CY1124418T1 (da)
DK (4)	DK3906918T3 (da)
EA (2)	EA201790978A1 (da)
ES (4)	ES2846809T3 (da)
FI (2)	FI3834823T3 (da)
HR (1)	HRP20210098T1 (da)
HU (4)	HUE067697T2 (da)
IL (7)	IL283699B (da)
LT (1)	LT3215133T (da)
MX (4)	MX383295B (da)
PL (1)	PL3215133T3 (da)
PT (1)	PT3215133T (da)
RS (1)	RS61359B1 (da)
SI (1)	SI3215133T1 (da)
WO (2)	WO2016073798A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010138193A2 (en)	2009-05-27	2010-12-02	Selecta Biosciences, Inc.	Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
WO2011150264A2 (en)	2010-05-26	2011-12-01	Selecta Biosciences, Inc.	Synthetic nanocarrier combination vaccines
WO2012061717A1 (en)	2010-11-05	2012-05-10	Selecta Biosciences, Inc.	Modified nicotinic compounds and related methods
MX373641B (es)	2011-04-29	2020-05-04	Selecta Biosciences Inc	Nanoportadores sintéticos tolerogénicos para la terapia contra alergias.
CA2843274A1 (en)	2011-07-29	2013-02-07	Selecta Biosciences, Inc.	Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
CN105283175A (zh)	2013-05-03	2016-01-27	西莱克塔生物科技公司	用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
WO2015025538A1 (ja) *	2013-08-20	2015-02-26	サンノプコ株式会社	バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法
KR20170045344A (ko)	2014-09-07	2017-04-26	셀렉타 바이오사이언시즈, 인크.	항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
US10125378B2 (en) *	2015-02-17	2018-11-13	San Nopco Ltd.	Additive for bioethanol fermentation process and method for producing bioethanol
US10973925B2 (en)	2015-04-28	2021-04-13	University Of Central Florida Research Foundation Inc.	Methods and compositions for theranostic nanoparticles
AU2017230891B2 (en)	2016-03-11	2024-04-18	Selecta Biosciences, Inc.	Formulations and doses of pegylated uricase
WO2018047443A1 (ja) *	2016-09-09	2018-03-15	花王株式会社	ジカルボン酸結晶及びその製造方法
US20180085319A1 (en)	2016-09-27	2018-03-29	Takashi Kei Kishimoto	Methods and compositions for treating cancer
AU2018205496A1 (en)	2017-01-07	2019-07-25	Selecta Biosciences, Inc.	Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
JP7523909B2 (ja)	2017-03-11	2024-07-29	セレクタバイオサイエンシーズインコーポレーテッド	抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物
BR112020007157A2 (pt)	2017-10-13	2020-09-24	Selecta Biosciences, Inc.	métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
WO2020154645A1 (en) *	2019-01-24	2020-07-30	Generation Bio Co.	Close-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response
JP2022531201A (ja)	2019-04-28	2022-07-06	セレクタバイオサイエンシーズインコーポレーテッド	ウイルス導入ベクターに対する既存の免疫を伴う対象の処置のための方法
AU2020284555A1 (en)	2019-05-28	2021-12-23	Selecta Biosciences, Inc.	Methods and compositions for attenuated anti-viral transfer vector immune response
JP7729783B2 (ja)	2019-06-04	2025-08-26	セレクタバイオサイエンシーズインコーポレーテッド	ペグ化ウリカーゼの処方物および用量
CN115038441A (zh) *	2019-10-21	2022-09-09	西莱克塔生物科技公司	用于治疗肝疾病和病症的方法和组合物
MX2022005506A (es)	2019-11-08	2022-08-10	Selecta Biosciences Inc	Formulaciones y dosis de uricasa pegilada.
US20210290601A1 (en)	2020-02-26	2021-09-23	Selecta Biosciences, Inc.	Methods and compositions using synthetic nanocarriers comprising immunosuppressant
AU2021236234A1 (en) *	2020-03-11	2022-10-06	Selecta Biosciences, Inc.	Methods and compositions related to synthetic nanocarriers
US20230147052A1 (en)	2020-04-14	2023-05-11	Selecta Biosciences, Inc.	Methods and compositions for inducing autophagy
US20220133864A1 (en)	2020-11-04	2022-05-05	Selecta Biosciences, Inc.	Methods and compositions for reducing immune responses against immunoglobulin proteases
EP4274571A1 (en)	2021-01-05	2023-11-15	Selecta Biosciences, Inc.	Viral vector dosing protocols
KR102304785B1 (ko)	2021-03-26	2021-09-24	(주)진성티앤피	정밀광학기기의 부품 제조 방법
US20220323607A1 (en)	2021-04-09	2022-10-13	Selecta Biosciences, Inc.	Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
JP2024515626A (ja)	2021-04-16	2024-04-10	アスクレピオスバイオファーマシューティカル，インコーポレイテッド	血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
WO2023064350A1 (en)	2021-10-12	2023-04-20	Selecta Biosciences, Inc.	Viral vector dosing protocols
WO2023064367A1 (en)	2021-10-12	2023-04-20	Selecta Biosciences, Inc.	Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023086615A1 (en)	2021-11-14	2023-05-19	Selecta Biosciences, Inc.	Multiple dosing with viral vectors
WO2023133319A1 (en)	2022-01-10	2023-07-13	Selecta Biosciences, Inc.	High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
US20230357437A1 (en)	2022-03-09	2023-11-09	Selecta Biosciences, Inc.	Immunosuppressants in combination with anti-igm agents and related dosing
US20230322884A1 (en)	2022-03-09	2023-10-12	Selecta Biosciences, Inc.	Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230381277A1 (en)	2022-04-08	2023-11-30	Selecta Biosciences, Inc.	High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
JP2025526816A (ja)	2022-08-11	2025-08-15	カーティザンセラピューティクス，インコーポレーテッド	免疫グロブリンプロテアーゼおよびその融合体に関する組成物および方法
WO2024107889A1 (en)	2022-11-15	2024-05-23	Selecta Biosciences, Inc.	Compositions and methods for treating primary biliary cholangitis
WO2024229432A1 (en)	2023-05-03	2024-11-07	Cartesian Therapeutics, Inc.	Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2024229350A1 (en)	2023-05-03	2024-11-07	Cartesian Therapeutics, Inc.	Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
WO2024229380A1 (en)	2023-05-03	2024-11-07	Cartesian Therapeutics, Inc.	Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2024229370A1 (en)	2023-05-03	2024-11-07	Cartesian Therapeutics, Inc.	Compositions and methods for treating gvhd
TWI877967B (zh) *	2023-12-28	2025-03-21	訊聯生物科技股份有限公司	包含小分子核糖核酸及奈米載體之組合物、包含其的醫藥組成物及其用途
WO2025256977A1 (en)	2024-06-13	2025-12-18	Bayer Aktiengesellschaft	Novel igm and igg cleaving enzymes
WO2025256978A1 (en)	2024-06-13	2025-12-18	Bayer Aktiengesellschaft	Variants of igm and igg cleaving enzymes

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946929A (en)	1983-03-22	1990-08-07	Massachusetts Institute Of Technology	Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4638045A (en)	1985-02-19	1987-01-20	Massachusetts Institute Of Technology	Non-peptide polyamino acid bioerodible polymers
US4806621A (en)	1986-01-21	1989-02-21	Massachusetts Institute Of Technology	Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
CA1340581C (en)	1986-11-20	1999-06-08	Joseph P. Vacanti	Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5759830A (en)	1986-11-20	1998-06-02	Massachusetts Institute Of Technology	Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5736372A (en)	1986-11-20	1998-04-07	Massachusetts Institute Of Technology	Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5019379A (en)	1987-07-31	1991-05-28	Massachusetts Institute Of Technology	Unsaturated polyanhydrides
US5010167A (en)	1989-03-31	1991-04-23	Massachusetts Institute Of Technology	Poly(amide-and imide-co-anhydride) for biological application
US5399665A (en)	1992-11-05	1995-03-21	Massachusetts Institute Of Technology	Biodegradable polymers for cell transplantation
US5512600A (en)	1993-01-15	1996-04-30	Massachusetts Institute Of Technology	Preparation of bonded fiber structures for cell implantation
US5514378A (en)	1993-02-01	1996-05-07	Massachusetts Institute Of Technology	Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5543158A (en)	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
US5565215A (en)	1993-07-23	1996-10-15	Massachusettes Institute Of Technology	Biodegradable injectable particles for imaging
US6007845A (en)	1994-07-22	1999-12-28	Massachusetts Institute Of Technology	Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en)	1994-12-16	1998-02-10	Massachusetts Institute Of Technology	Breast tissue engineering
US6123727A (en)	1995-05-01	2000-09-26	Massachusetts Institute Of Technology	Tissue engineered tendons and ligaments
US6095148A (en)	1995-11-03	2000-08-01	Children's Medical Center Corporation	Neuronal stimulation using electrically conducting polymers
US5902599A (en)	1996-02-20	1999-05-11	Massachusetts Institute Of Technology	Biodegradable polymer networks for use in orthopedic and dental applications
AU735648B2 (en)	1996-07-12	2001-07-12	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
US7288266B2 (en)	1996-08-19	2007-10-30	United States Of America As Represented By The Secretary, Department Of Health And Human Services	Liposome complexes for increased systemic delivery
US5837752A (en)	1997-07-17	1998-11-17	Massachusetts Institute Of Technology	Semi-interpenetrating polymer networks
US6187335B1 (en)	1997-12-31	2001-02-13	Orasomal Technologies, Inc.	Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US6506577B1 (en)	1998-03-19	2003-01-14	The Regents Of The University Of California	Synthesis and crosslinking of catechol containing copolypeptides
US6632922B1 (en)	1998-03-19	2003-10-14	The Regents Of The University Of California	Methods and compositions for controlled polypeptide synthesis
US6686446B2 (en)	1998-03-19	2004-02-03	The Regents Of The University Of California	Methods and compositions for controlled polypeptide synthesis
JP2002521423A (ja)	1998-07-31	2002-07-16	コリアインスティチュートオブサイエンスアンドテクノロージ	遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
CA2731995C (en) *	1998-09-01	2013-05-28	Merrion Research Iii Limited	Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
US6632671B2 (en)	2000-02-28	2003-10-14	Genesegues, Inc.	Nanoparticle encapsulation system and method
US6818732B2 (en)	2001-08-30	2004-11-16	The Regents Of The University Of California	Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US20040038303A1 (en) *	2002-04-08	2004-02-26	Unger Gretchen M.	Biologic modulations with nanoparticles
AU2003270102B2 (en)	2002-08-23	2008-10-02	Medigene Ag	Non-vesicular cationic lipid formulations
CN1886100A (zh) *	2003-11-14	2006-12-27	阿尔萨公司	基于表面活性剂的凝胶作为可注射的持续药物递送载体
US20050260260A1 (en)	2004-05-19	2005-11-24	Edward Kisak	Liposome compositions for the delivery of macromolecules
CA2620389C (en) *	2005-08-31	2014-06-17	Abraxis Bioscience, Llc	Compositions and methods for preparation of poorly water soluble drugs with increased stability
US8414910B2 (en) *	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
CA2917512C (en)	2007-10-12	2025-08-05	President And Fellows Of Harvard College	VACCINE NANOTECHNOLOGY
US8613951B2 (en) *	2008-06-16	2013-12-24	Bind Therapeutics, Inc.	Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
DK2774608T3 (da) *	2008-06-16	2020-01-13	Pfizer	Lægemiddelladede polymere nanopartikler og fremgangsmåder til fremstilling og anvendelse deraf
CN101676291B (zh)	2008-09-18	2012-05-09	上海海和药物研究开发有限公司	一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
EA201100765A1 (ru) *	2008-12-15	2012-04-30	Бинд Биосаиэнсис	Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
KR101267813B1 (ko) *	2009-12-30	2013-06-04	주식회사 삼양바이오팜	향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
AU2011303849A1 (en) *	2010-09-14	2013-04-04	Nanologica Ab	Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients
WO2012059936A1 (en) *	2010-11-03	2012-05-10	Padma Venkitachalam Devarajan	Pharmaceutical compositions for colloidal drug delivery
MX373641B (es) *	2011-04-29	2020-05-04	Selecta Biosciences Inc	Nanoportadores sintéticos tolerogénicos para la terapia contra alergias.
CN102793674B (zh) *	2011-05-26	2014-11-26	澳门科技大学	一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用
US20150272885A1 (en)	2011-10-14	2015-10-01	Stc.Unm	Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
TWI439288B (zh) *	2012-10-05	2014-06-01	Univ China Medical	藥用載體及其製備方法與用途
CN102871966B (zh) *	2012-10-19	2013-11-20	东南大学	用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法

2015
- 2015-11-05 IL IL283699A patent/IL283699B/en unknown
- 2015-11-05 HR HRP20210098TT patent/HRP20210098T1/hr unknown
- 2015-11-05 EP EP21156943.9A patent/EP3906918B1/en active Active
- 2015-11-05 HU HUE21156943A patent/HUE067697T2/hu unknown
- 2015-11-05 EA EA201790978A patent/EA201790978A1/ru unknown
- 2015-11-05 IL IL296246A patent/IL296246A/en unknown
- 2015-11-05 JP JP2017524451A patent/JP7218089B2/ja active Active
- 2015-11-05 SI SI201531494T patent/SI3215133T1/sl unknown
- 2015-11-05 CA CA2966850A patent/CA2966850C/en active Active
- 2015-11-05 DK DK21156943.9T patent/DK3906918T3/da active
- 2015-11-05 CN CN202110403075.4A patent/CN113244191A/zh active Pending
- 2015-11-05 EP EP20204014.3A patent/EP3834823B1/en active Active
- 2015-11-05 HU HUE20204014A patent/HUE066099T2/hu unknown
- 2015-11-05 HU HUE15798601A patent/HUE053094T2/hu unknown
- 2015-11-05 CN CN201580060789.2A patent/CN107072965B/zh active Active
- 2015-11-05 WO PCT/US2015/059349 patent/WO2016073798A1/en not_active Ceased
- 2015-11-05 DK DK15857076.2T patent/DK3215192T3/da active
- 2015-11-05 ES ES15798601T patent/ES2846809T3/es active Active
- 2015-11-05 AU AU2015342968A patent/AU2015342968B2/en active Active
- 2015-11-05 BR BR122021025344-7A patent/BR122021025344B1/pt active IP Right Grant
- 2015-11-05 FI FIEP20204014.3T patent/FI3834823T3/fi active
- 2015-11-05 CN CN202210754573.8A patent/CN115212187A/zh active Pending
- 2015-11-05 AU AU2015342969A patent/AU2015342969B2/en active Active
- 2015-11-05 MX MX2017005903A patent/MX383295B/es unknown
- 2015-11-05 EP EP23220853.8A patent/EP4360633A3/en not_active Withdrawn
- 2015-11-05 LT LTEP15798601.9T patent/LT3215133T/lt unknown
- 2015-11-05 RS RS20210097A patent/RS61359B1/sr unknown
- 2015-11-05 KR KR1020177014831A patent/KR102601922B1/ko active Active
- 2015-11-05 PL PL15798601T patent/PL3215133T3/pl unknown
- 2015-11-05 CN CN202210754468.4A patent/CN115212186A/zh active Pending
- 2015-11-05 BR BR112017008499-6A patent/BR112017008499B1/pt active IP Right Grant
- 2015-11-05 KR KR1020177014830A patent/KR102656139B1/ko active Active
- 2015-11-05 JP JP2017524450A patent/JP6912377B2/ja active Active
- 2015-11-05 CN CN201580059855.4A patent/CN107072964A/zh active Pending
- 2015-11-05 US US14/934,132 patent/US20160128986A1/en active Pending
- 2015-11-05 FI FIEP21156943.9T patent/FI3906918T3/fi active
- 2015-11-05 US US14/934,135 patent/US20160128987A1/en not_active Abandoned
- 2015-11-05 ES ES20204014T patent/ES2977158T3/es active Active
- 2015-11-05 BR BR112017008720A patent/BR112017008720A2/pt not_active Application Discontinuation
- 2015-11-05 WO PCT/US2015/059350 patent/WO2016073799A1/en not_active Ceased
- 2015-11-05 DK DK15798601.9T patent/DK3215133T3/da active
- 2015-11-05 EP EP15857076.2A patent/EP3215192B1/en active Active
- 2015-11-05 CA CA2966852A patent/CA2966852C/en active Active
- 2015-11-05 EP EP15798601.9A patent/EP3215133B1/en active Active
- 2015-11-05 IL IL295292A patent/IL295292B2/en unknown
- 2015-11-05 DK DK20204014.3T patent/DK3834823T3/da active
- 2015-11-05 EP EP23220845.4A patent/EP4356910A3/en not_active Withdrawn
- 2015-11-05 MX MX2017005904A patent/MX386982B/es unknown
- 2015-11-05 PT PT157986019T patent/PT3215133T/pt unknown
- 2015-11-05 EA EA201790977A patent/EA201790977A1/ru unknown
- 2015-11-05 ES ES21156943T patent/ES2977259T3/es active Active
- 2015-11-05 HU HUE15857076A patent/HUE054894T2/hu unknown
- 2015-11-05 ES ES15857076T patent/ES2865375T3/es active Active
2017
- 2017-04-06 IL IL251620A patent/IL251620B/en active IP Right Grant
- 2017-04-06 IL IL251622A patent/IL251622B/en active IP Right Grant
- 2017-05-04 MX MX2021006698A patent/MX2021006698A/es unknown
- 2017-05-04 MX MX2021012273A patent/MX2021012273A/es unknown
2021
- 2021-01-27 CY CY20211100063T patent/CY1124418T1/el unknown
- 2021-01-31 IL IL280518A patent/IL280518B/en unknown
- 2021-05-10 JP JP2021080003A patent/JP2021143180A/ja active Pending
- 2021-07-27 AU AU2021209204A patent/AU2021209204A1/en not_active Abandoned
- 2021-07-27 AU AU2021209202A patent/AU2021209202B2/en active Active
- 2021-12-02 IL IL288609A patent/IL288609B2/en unknown
2022
- 2022-09-01 JP JP2022139392A patent/JP2022173236A/ja active Pending
2023
- 2023-07-03 JP JP2023109379A patent/JP2023169893A/ja active Pending
2024
- 2024-10-21 US US18/921,868 patent/US20250152561A1/en active Pending

Also Published As

Publication number	Publication date
IL295292A (en)	2022-10-01
SI3215133T1 (sl)	2021-07-30
CN107072965B (zh)	2021-05-11
MX2021012273A (es)	2021-11-12
FI3834823T3 (fi)	2024-04-02
CA2966850A1 (en)	2016-05-12
AU2021209204A1 (en)	2021-08-19
IL288609B2 (en)	2023-02-01
CN115212187A (zh)	2022-10-21
IL288609A (en)	2022-02-01
JP7218089B2 (ja)	2023-02-06
MX2017005904A (es)	2017-06-27
JP2023169893A (ja)	2023-11-30
EP4360633A2 (en)	2024-05-01
CN107072964A (zh)	2017-08-18
HUE067697T2 (hu)	2024-11-28
EP4356910A3 (en)	2024-05-22
IL288609B (en)	2022-10-01
PL3215133T3 (pl)	2021-06-14
IL251620A0 (en)	2017-06-29
AU2021209202B2 (en)	2023-11-30
IL283699A (en)	2021-07-29
US20250152561A1 (en)	2025-05-15
MX2017005903A (es)	2017-06-27
ES2977158T3 (es)	2024-08-20
AU2015342968A1 (en)	2017-04-27
AU2021209202A1 (en)	2021-08-19
ES2846809T3 (es)	2021-07-29
BR122021025344B1 (pt)	2024-02-20
WO2016073799A1 (en)	2016-05-12
IL280518B (en)	2022-01-01
HUE066099T2 (hu)	2024-07-28
EP3215192B1 (en)	2021-02-17
LT3215133T (lt)	2021-02-25
MX383295B (es)	2025-03-13
US20160128987A1 (en)	2016-05-12
IL296246A (en)	2022-11-01
MX2021006698A (es)	2021-07-07
IL295292B1 (en)	2024-06-01
EP3215192A1 (en)	2017-09-13
WO2016073799A9 (en)	2016-12-08
CY1124418T1 (el)	2022-07-22
EP3215133B1 (en)	2020-10-28
KR102601922B1 (ko)	2023-11-15
CN107072965A (zh)	2017-08-18
EP3215192A4 (en)	2018-05-02
ES2865375T3 (es)	2021-10-15
EP3834823A1 (en)	2021-06-16
RS61359B1 (sr)	2021-02-26
EA201790978A1 (ru)	2017-09-29
JP2017533243A (ja)	2017-11-09
EP3906918B1 (en)	2024-01-03
IL283699B (en)	2022-09-01
BR112017008499A2 (pt)	2017-12-26
CA2966852C (en)	2024-01-02
KR20170081660A (ko)	2017-07-12
EP3215133A1 (en)	2017-09-13
KR20170081659A (ko)	2017-07-12
JP2021143180A (ja)	2021-09-24
JP2017537081A (ja)	2017-12-14
AU2015342969B2 (en)	2021-05-27
JP2022173236A (ja)	2022-11-18
BR112017008499B1 (pt)	2023-10-03
WO2016073798A1 (en)	2016-05-12
HUE054894T2 (hu)	2021-10-28
EA201790977A1 (ru)	2017-10-31
IL295292B2 (en)	2024-10-01
FI3906918T3 (fi)	2024-04-04
DK3215192T3 (da)	2021-05-03
EP3834823B1 (en)	2024-01-03
JP6912377B2 (ja)	2021-08-04
CA2966852A1 (en)	2016-05-12
EP4356910A2 (en)	2024-04-24
HRP20210098T1 (hr)	2021-03-05
IL280518A (en)	2021-03-01
EP4360633A3 (en)	2024-05-22
CA2966850C (en)	2024-03-26
BR112017008720A2 (pt)	2017-12-19
IL251620B (en)	2021-02-28
IL251622B (en)	2021-06-30
CN113244191A (zh)	2021-08-13
IL251622A0 (en)	2017-06-29
KR102656139B1 (ko)	2024-04-11
PT3215133T (pt)	2021-01-29
CN115212186A (zh)	2022-10-21
DK3906918T3 (da)	2024-04-08
ES2977259T3 (es)	2024-08-21
US20160128986A1 (en)	2016-05-12
AU2015342969A1 (en)	2017-04-27
MX386982B (es)	2025-03-19
AU2015342968B2 (en)	2021-05-27
EP3906918A1 (en)	2021-11-10
DK3215133T3 (da)	2021-02-01
HUE053094T2 (hu)	2021-06-28

Publication	Publication Date	Title
DK3834823T3 (da)	2024-04-08	Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog
NO2023013I1 (no)	2023-03-20	Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent
BR112016030968A2 (pt)	2018-07-17	análogos de pridopidina, preparação e uso destes
CO6831975A2 (es)	2014-01-10	Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
DK3143011T3 (da)	2021-05-03	Deutererede heterocykliske forbindelser og deres anvendelse som billeddannende stoffer
DK3308688T3 (da)	2022-05-09	Opvaskemaskine i form af en kommerciel bestikopvaskemaskine eller opvaskemaskine, designet som en batch-opvaskemaskine
BR112017015946A2 (pt)	2018-07-10	composições de oligossacarídeo para uso como ingredientes alimentares e métodos para produzir as mesmas
SG11201707992QA (en)	2017-10-30	Cosmetic composition using plant-derived natural surfactant
SG11201707249QA (en)	2017-10-30	Anti-reflective and anti-fogging materials
PL3223796T3 (pl)	2021-12-20	Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania
PL3229591T3 (pl)	2019-04-30	Surfaktanty cukrowe i ich zastosowanie w kompozycjach agrochemicznych
IL253368B (en)	2021-01-31	Oil blends, processes for the preparation thereof and their use in formulas
IL253530B (en)	2021-12-01	Titanium inks, methods of making and using the same to make titanium articles
LT3229790T (lt)	2019-12-10	Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme
EP3307234A4 (en)	2018-11-14	Flavolipids as surfactants in cleansing compositions
IL247531A0 (en)	2016-11-30	The history of ksuz, their preparation and uses
ZA201608621B (en)	2017-09-27	Silicon-containing azodicarboxamides, their preparation and use
EP3102557A4 (en)	2017-11-15	Improved compositions and methods comprising resveratrol
CO6900155A2 (es)	2014-03-20	Composiciones estables y métodos para su preparación
ES1135057Y (es)	2015-03-20	Taburete para uso en antropometria
TH1601000111A (th)	2017-10-12	น้ำยาทำความสะอาดส่วนบุคคลและส่วนผสมสารลดแรงตึงผิวสำหรับสิ่งนั้น
TWM489067U (en)	2014-11-01	Blade and handle combination structure of saw
HK1240091A1 (en)	2018-05-18	Mucolytic agents for use in tretaing pulmonary sarcoidosis
GB201500975D0 (en)	2015-03-04	Dimeric surfactants and their preparation
TH1601000482A (th)	2017-10-12	องค์ประกอบสารชะล้างผิว